Nephrogenic systemic fibrosis is not exclusively associated with gadodiamide

European Radiology

Volumn 17, Issue 8, 2007, Pages 1921-1923

  Leiner, Tim ^a,b   Herborn, Christoph U ^c   Goyen, Mathias ^c  

^a MAASTRICHT UNIVERSITY   (Netherlands)

^b MAASTRICHT UNIVERSITY   (Netherlands)

^c UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CHELATING AGENT; GADOBENATE DIMEGLUMINE; GADOBUTROL; GADODIAMIDE; GADOFOSVESET; GADOLINIUM; GADOLINIUM PENTETATE; GADOTERATE MEGLUMINE; GADOTERIDOL; GADOVERSETAMIDE; GADOXETIC ACID;

DRUG CONTRAINDICATION; DRUG DOSE COMPARISON; DRUG SURVEILLANCE PROGRAM; EDITORIAL; GLOMERULUS FILTRATION RATE; HEMODIALYSIS; HISTOPATHOLOGY; HUMAN; KIDNEY FAILURE; KIDNEY FIBROSIS; LIVER TRANSPLANTATION; NEPHROGENIC SYSTEMIC FIBROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOGENESIS; PERITONEAL DIALYSIS; PRIORITY JOURNAL; PUBLICATION; RISK ASSESSMENT;

CONTRAST MEDIA; FIBROSIS; GADOLINIUM DTPA; HUMANS; KIDNEY FAILURE, CHRONIC; MAGNETIC RESONANCE IMAGING; SKIN DISEASES;

EID: 34547106279     PISSN: 09387994     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00330-007-0663-5     Document Type: Editorial

References (15)

1. Thomsen H (2006) Nephrogenic systemic fibrosis: A serious late adverse reaction to gadodiamide. Eur Radiol 16:2619-2621
2. Cowper SE, Robin HS, Steinberg SM, Su LD, Gupta S, LeBoit PE (2000) Scleromyxoedema-like cutaneous diseases in renal-dialysis patients. Lancet 356:1000-1001
3. Cowper SE (2007) Nephrogenic fibrosing dermopathy (NFD/NSF Web site). 2001-2007. Available at http://www.icnfdr.org. Accessed March 22, 2007.
4. High WA, Ayers RA, Chandler J, Zito G, Cowper SE (2007) Gadolinium is detectable within the tissue of patients with nephrogenic systemic fibrosis. J Am Acad Dermatol 56:21-26
5. Grobner T (2006) Gadolinium - a specific trigger for the development of nephrogenic fibrosing dermopathy and nephrogenic systemic fibrosis? Nephrol Dial Transplant 21:1104-1108
6. Collidge TA, Thompson PC, Mark PB, Traynor JP, Jardine A, Morris STW, Simpson K, Roditi G (2007) Gadolinium-enhanced magnetic resonance imaging and nephrogenic systemic fibrosis - a retrospective case-control Study. Radiology (in press)
7. Marckmann P, Skov L, Rossen K, Dupont A, Damholt MB, Heaf JG, Thomsen HS (2006) Nephrogenic systemic fibrosis: Suspected causative role of gadodiamide used for contrast-enhanced magnetic resonance imaging. J Am Soc Nephrol 17:2359-2362
8. United States Food and Drug Administration, Rockville, MD, USA. Public Health Advisory. Gadolinium-containing contrast agents for magnetic resonance imaging (MRI): Omniscan, OptiMARK, Magnevist, ProHance and Multihance. Available from URL: http://www.fda.gov/cder/drug/advisory/ gadolinium_agents.htm. (Accessed March 22, 2007)
9. European Society for Magnetic Resonance in Medicine and Biology. Vienna, Austria. Available from URL: http://www.esmrmb.org/index.php?pid= 587&SID=5bbbc5f75411bab76e4aee221e8eacdf. (Accessed March 30, 2007)
10. Idée J-M, Port M, Raynal I, Schaefer M, Le Greneur S, Corot C (2006) Clinical and biological consequences of transmetallation induced by contrast agents for magnetic resonance imaging: A review. Fundam Clin Pharmacol 20:563-576
11. Boyd AS, Zic JA, Abraham JL (2007) Gadolinium deposition in nephrogenic fibrosing dermopathy. J Am Acad Dermatol 56:27-30
12. Kuo PH, Kanal E, Abu-Alfa AK, Cowper SE (2007) Gadolinium-based MR contrast agents and nephrogenic systemic fibrosis. Radiology 242:647-649
13. Sadowski EA, Bennett LK, Chan MR, Wentland AL, Garrett AL, Garret RW, Djamali A (2007) Nephrogenic systemic fibrosis: Risk factors and incidence estimation. Radiology 242(3):647-649
14. GE Healthcare, Buckinghamshire, United Kingdom. GE Healthcare paper on nephrogenic systemic fibrosis, March 2007. Available from URL: http://www.amershamhealth-us.com/omniscan/GE%20Healthcare% 20Paper%20On%20Nephrogenic%20Systemic%20Fibrosis.pdf. (Accessed March 30, 2007)
15. Bayer Schering Pharma AG, Berlin, Germany. NSF/NFD Update. Available from URL: http://www.berleximaging.com/html/magnevist/nsf_nfd.html. (Accessed March 23, 2007)